ArticleAnalytical and bioanalytical chemistry2025
A new wide-scope, multi-biomarker wastewater-based epidemiology analytical method to monitor the health and well-being of inhabitants at a metropolitan scale.
Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancing analytical methodologies for the determination of lifestyle and dietary biomarkers in municipal wastewater.Analytical and bioanalytical chemistry · 2026Article
- A new multi-residue method for PFAS analysis in wastewater for environmental and public health risk assessment.Analytical and bioanalytical chemistry · 2026Article
- Understanding the Role of Deconjugation of Phase II Metabolites in Wastewater: Implications for Wastewater-Based Epidemiology.Environmental science & technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This manuscript establishes a new, comprehensive biomarker list and a multiresidue trace quantification method for community-wide health and well-being assessment at a metropolitan scale using wastewater-based epidemiology (WBE) and mass spectrometry pipelines. This method enables the quantification of 204 biochemical indicators (BCIs) across a range of biomarker classes within influent wastewater and includes illicit drug BCIs, pharmaceuticals as proxies for disease, health markers (hormones, oxidative stress, lipid peroxidation, etc.), Lifestyle chemicals, food BCIs, and hazardous chemicals in personal care products. This method facilitates the combined assessment of community exposure to chemicals and the effects of this exposure in the same framework. The method enables full quantification of 141 BCIs with method detection Limits varying from 0.01 ng/L for amlodipine to 23.8 ng/L for stachydrine. Total average method accuracies were 102.7% whereas precision was 10.4%. During an initial assessment of this method to test its suitability, 62% of all targets were detected and quantified during a week-long feasibility study of a large city with weekly average Daily BCI loads ranging from 40.0 ± 20.0 mg/day for salbutamol to 5836.5 ± 1697.1 g/day for creatinine. The inclusion of new endogenous markers such as advanced glycation end products, detected in wastewater for the first time, enables more accurate determination of community-level health and lifestyle habits. Alongside an unbiased and comprehensive health assessment through endogenous markers, health is further assessed via the use of pharmaceuticals, acting as a proxy for health and disease status whilst additionally providing insights into community lifestyle habits through the monitoring of licit/illicit drug use and food consumption. The analysis of all biomarker classes combined aims to provide insights to exposure and health effect outcomes at the community level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.